KALA BIO, Inc. (KALA)
NASDAQ: KALA · Real-Time Price · USD
5.74
-0.23 (-3.85%)
At close: Jul 18, 2025, 4:00 PM
5.69
-0.05 (-0.87%)
After-hours: Jul 18, 2025, 6:42 PM EDT
KALA BIO Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
38
Market Cap
37.04M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
Novartis AG | 55.19B |
AstraZeneca | 54.98B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
KALA News
- 11 days ago - KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) - GlobeNewsWire
- 7 weeks ago - KALA BIO to Present at Jefferies Global Healthcare Conference - GlobeNewsWire
- 5 months ago - KALA BIO Announces Chief Executive Officer Transition - GlobeNewsWire
- 7 months ago - KALA BIO Announces $10,750,000 Private Placement - GlobeNewsWire
- 8 months ago - KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference - GlobeNewsWire
- 1 year ago - KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 1 year ago - KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 1 year ago - KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference - GlobeNewsWire